# A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

> **NCT02364999** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 719 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Bevacizumab-Pfizer
- **DRUG:** Bevacizumab-EU
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02364999
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2017-05
- **Final completion:** 2017-12
- **Target enrollment:** 719 (ACTUAL)
- **Last updated:** 2019-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02364999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02364999, "A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02364999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*